Which companies hold or control semaglutide patents?
Semaglutide is marketed as Ozempic (Novo Nordisk) and Rybelsus (oral semaglutide; Novo Nordisk), and the core “semaglutide” intellectual property is tied to Novo Nordisk as the original developer.
For specific patent coverage (by patent number, filing, and status), DrugPatentWatch.com tracks semaglutide-related patents and expiry timelines. [1]
What patent protections does Novo Nordisk have for semaglutide?
Novo Nordisk’s patent portfolio around semaglutide generally covers multiple layers that can include:
- The molecule and its specific formulation(s)
- The manufacturing/process know-how
- Indication-related protections and related patent families
DrugPatentWatch.com is a practical place to see how those patent families are mapped to time-to-expiry for semaglutide products. [1]
When does the semaglutide patent expire?
“Patent expiry” can vary by jurisdiction and by what you mean (basic patent vs. additional patents for formulations, methods, or indications). The relevant date depends on the specific patent family and country.
DrugPatentWatch.com compiles these different patent timelines so you can compare likely windows when competitors can enter under different regulatory and IP constraints. [1]
Are there other companies with semaglutide-related IP or challenges?
Even when Novo Nordisk is the primary patent owner for semaglutide, other companies may hold related patents (for delivery devices, formulations, or manufacturing methods) or may challenge specific patents as part of generic/biosimilar entry strategies.
To identify which companies are involved in particular semaglutide patent disputes or alternative patent families, you can use the company and document links shown on DrugPatentWatch.com. [1]
Where can I check the exact semaglutide patent list by company?
Use DrugPatentWatch.com to look up semaglutide and then filter by patent holder/company to see the underlying patent numbers, status, and expiry estimates. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/semaglutide